---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062474"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:52:05.219728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial

## Summary
- Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.
- Cash and cash equivalents $27.0M at Sep 30, 2023, down $0.9M from Mar 31, 2023; $7.5M private placement closed in Sep 2023.
- First patient enrolled in STRIVE-ON Phase 3 trial of GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).
- GTX-104 NDA submission to FDA on track for first half of 2025.
- Private placement led by ADAR1 Partners; proceeds to fund Phase 3 trial, NDA prep, and working capital.

## SEC filing metadata
- accession: 0000950170-23-062474
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/0000950170-23-062474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/acst-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062474
- JSON: https://secwatch.observer/filing/0000950170-23-062474.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062474.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported three months ended September 30, 2023 results: net income Net loss $3.3 million or $0.43 per share, EPS $0.43 per share.
  - Period: three months ended September 30, 2023
  - Net income: Net loss $3.3 million or $0.43 per share
  - EPS: $0.43 per share
  - Result: reported results
  source text: Net loss $3.3 million or $0.43 per share for the three months ended September 30, 2023 decreased by $1.7 million from the net loss of $5.0 million or $0.66 per share for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/0000950170-23-062474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.